LONDON — Consumer goods group Reckitt Benckiser is reviewing options for its pharmaceuticals unit, it said yesterday, effectively putting up for sale its prescription medicine for heroin addiction which faces cheap, copycat competition.
Reuters
Shares in the British company rose over 4,5% in early trading. Bank of America Merrill Lynch has valued the pharmaceuticals unit at about 2 billion pounds ($3,2 billion).
The business centers around the drug Suboxone, which Reckitt sells as a film that dissolves in the mouth. It is used to treat addiction to opioids like heroin. In the third quarter, its revenue fell 14% to 191 million pounds.
The company, which also sells cleaning products and over-the-counter medicines, had said before that the right time to consider options for the pharmaceutical business would be following the launch of cheap, generic Suboxone tablets.
In February, US regulators approved two generic versions of the drug. It expects the review to take some time, and said it would update shareholders during the course of 2014.
Reckitt also reported a 5% rise in third-quarter revenue, which brought year-to-date revenue above analysts’ estimates.
For the first nine months of the year, total revenue, excluding the pharmaceuticals business, was 6,95 billion pounds. Analysts on average were expecting 6,93 billion pounds, according to a company-provided consensus.
- Chamisa under fire over US$120K donation
- Mavhunga puts DeMbare into Chibuku quarterfinals
- Pension funds bet on Cabora Bassa oilfields
- Councils defy govt fire tender directive
Keep Reading
Reckitt cited strength in emerging markets.
Looking ahead, the company nudged up its target for full-year net revenue growth, excluding the pharmaceuticals business and including the impact of acquisitions and divestments.
It now expects a rise of at least 6%, whereas it earlier forecast growth at the high end of the 5% to 6% range. The company cited strength of its recent acquisitions for the increase.
